KRAS and pancreatic neoplasm: These effects were not confined to the WM1366 cell line as dabrafenib also exhibited long‐term growth suppression of other RAS‐mutant melanoma cancer cell lines, including IPC‐298 (NRAS mutant) and M249R cells (a cell line that was initially BRAF mutant and acquired an NRAS mutation upon BRAF inhibitor resistance) (Nazarian et al., 2010)(Fig. 1C) and two KRAS‐mutant pancreatic cancer cell lines (Capan‐1 and MIA PaCa‐2) (Fig. 1D).